603 results about "Atheromatosis" patented technology

The disclosure herein relates to systems, methods, and devices for medical image analysis, diagnosis, risk stratification, decision making and / or disease tracking. In some embodiments, the systems, devices, and methods described herein are configured to analyze non-invasive medical images of a subject to automatically and / or dynamically identify one or more features, such as plaque and vessels, and / or derive one or more quantified plaque parameters, such as radiodensity, radiodensity composition, volume, radiodensity heterogeneity, geometry, location, perform computational fluid dynamics analysis, facilitate assessment of risk of heart disease and coronary artery disease, enhance drug development, determine a CAD risk factor goal, provide atherosclerosis and vascular morphology characterization, and determine indication of myocardial risk, and / or the like. In some embodiments, the systems, devices, and methods described herein are further configured to generate one or more assessments of plaque-based diseases from raw medical images using one or more of the identified features and / or quantified parameters.

The disclosure herein relates to systems, methods, and devices for medical image analysis, diagnosis, risk stratification, decision making and / or disease tracking. In some embodiments, the systems, devices, and methods described herein are configured to analyze non-invasive medical images of a subject to automatically and / or dynamically identify one or more features, such as plaque and vessels, and / or derive one or more quantified plaque parameters, such as radiodensity, radiodensity composition, volume, radiodensity heterogeneity, geometry, location, perform computational fluid dynamics analysis, facilitate assessment of risk of heart disease and coronary artery disease, enhance drug development, determine a CAD risk factor goal, provide atherosclerosis and vascular morphology characterization, and determine indication of myocardial risk, and / or the like. In some embodiments, the systems, devices, and methods described herein are further configured to generate one or more assessments of plaque-based diseases from raw medical images using one or more of the identified features and / or quantified parameters.

The present invention discloses a pharmaceutical composition comprising a circular RNA and a drug delivery carrier. Compared with traditional linear 1 * siRNA and annular 1 * siRNA, the number of repeated series connection of positive-sense strands is increased to include but not limited to two or more, it is accidentally found that the silence effect is remarkably enhanced, the expression level of the PCSK9 gene can be remarkably reduced, and degradation of mRNA of PCSK9 protein is mediated. The nano-particles are used for delivering oligonucleotide, so that the stability is improved, the immunogenicity is reduced, the effects of lowering cholesterol, reducing aortic plaque load and resisting atherosclerosis are improved, and the nano-particles are safe and free of obvious liver and kidney toxicity and have a wide application prospect in the aspect of preparing medicines for treating hypercholesterolemia and coronary heart disease.

This disclosure relates to systems, methods, and devices for plaque analysis, vessel and fluid flow analysis, and / or risk determination or prediction thereof. Some embodiments relate to determining fractional flow reserve (FFR) values. Some embodiments relate to determining FFR values using 3D-printed models. Some embodiments relate to identifying thin cap fibroatheroma based on analysis of computed tomography (CT) imaging. Some embodiments relate adjusting calcified plaque thresholds for CT images to address effects of calcium blooming.

The invention relates to the technical field of atherosclerosis related drugs, in particular to a macrophage membrane functionalized manganese dioxide nano-drug as well as a preparation method and application thereof in treatment of atherosclerosis. The invention relates to a macrophage membrane functionalized manganese dioxide nano-drug, which comprises an HMnO2 carrier, colchicine is loaded on the HMnO2 carrier, and a macrophage membrane is coated outside the HMnO2 carrier. The preparation can be applied to practical operation of preparing medicines for treating atherosclerosis. According to the technical scheme, the technical problem of limited treatment effect caused by single action mechanism of medicines for treating atherosclerosis in the prior art can be solved. The nano-drug in the scheme can remove ROS to play an anti-inflammatory effect, reprogram macrophages and promote cholesterol excretion, and is used for synergistically treating atherosclerosis. The macrophage membrane can target an inflammation part and escape from an immune system. And the side effect of the nano-drug is relatively small, so that the nano-drug has ideal popularization and application prospects.

The present invention provides a method for increasing glycemic control in a patient in need thereof, by administering tirzepatide, or a pharmaceutically acceptable salt thereof. The present invention provides a method for improving weight management in a patient in need thereof, by administering tirzepatide, or a pharmaceutically acceptable salt thereof. Further providing a method for treating a condition selected from atherosclerosis, chronic kidney disease, NAFLD, and NASH. Further provided is a method to prevent or induce remission of diabetes comprising administration of tirzepatide, or a pharmaceutically acceptable salt thereof. Further provided is a dosing regimen for increasing glycemic control, improving weight management, and / or treating dyslipidemia.

Provided is a pharmaceutical composition, comprising a circular RNA and a drug delivery carrier. It is surprisingly found that compared with conventional linear 1 x siRNAs and circular 1 x siRNAs, increasing the number of tandem repeats in the sense strand to two or more significantly enhances the silencing effect, significantly reduces the expression level of the PCSK9 gene, and mediates the degradation of the PCSK9 protein mRNA. The use of nano-particles for delivering oligonucleotides features improved stability, reduced immunogenicity, improved cholesterol-lowering, aortic plaque load-reducing and anti-atherosclerotic effects, good safety, no significant liver and kidney toxicity, and therefore good prospects in preparing medicaments for treating hypercholesterolemia and a coronary heart disease.

The invention discloses a bionic nano-composite, a preparation method thereof and application of the bionic nano-composite in preparation of a product for treating atherosclerosis, and belongs to the technical field of medicine preparation. The bionic nano compound is a metal nano enzyme Ir-TiO2 coated by an M2 macrophage cell membrane. According to the invention, the surfaces of Ir-TiO2 nanoparticles are coated with M2 macrophage membranes, so that the nanocomposite with a bionic structure is prepared. After intravenous injection, the formed bionic nanocomposite can actively target endothelial cells in atherosclerotic lesions, and release Ir-TiO2 antagonism to endothelial cells in plaques and cytoplasm of inflammatory macrophages. After the Ir-TiO2 reaches the diseased region, the Ir-TiO2 can play an enzyme role to achieve an anti-inflammatory effect, and can promote inflammatory cells such as macrophages and smooth muscle cells at the diseased region to discharge cholesterol, reduce lipid deposition in the cells, reduce the generation of foam cells and promote the growth of plaques. The nanotherapy can effectively prevent the progress of atherosclerosis lesion inflammation and relieve atherosclerosis.

The invention relates to pediococcus acidilactici XZ106, which is classified and named as pediococcus acidilactici, and is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.30094, the preservation date is March 22, 2024, and the preservation address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing. The pediococcus acidilactici XZ106 can (1) relieve insulin resistance, regulate insulin and glucagon secretion and improve liver gluconeogenesis, so that diabetes hyperglycemia is improved; (2) weight gain, fat accumulation and liver lipid accumulation of obese mice are inhibited, glycolipid metabolism disorder of the mice is improved, and the composition has excellent effects of reducing fat and relieving obesity; (3) the level of IL-10 can be remarkably improved, and the anti-inflammatory ability of mice is improved; (4) vascular injury is reduced, so that diabetic complications and various cardiovascular diseases of atherosclerosis are prevented.

The invention discloses an ultrasonic molecular probe. The ultrasonic molecular probe comprises a targeted contrast agent and siRNA of fibronectin, wherein the targeted contrast agent and the siRNA are connected through G0-C14; the targeted contrast agent comprises gas vesicles covalently linked with annular polypeptide, and the annular polypeptide targets an atherosclerotic plaque region. The cyclic polypeptide can be combined with the outer structural domain B of fibronectin with high specificity, and the atherosclerotic plaque extracellular matrix is rich in the outer structural domain B of the fibronectin, so that enough targeted ultrasonic contrast agent can be quickly combined in the plaque region to generate strong signal enhancement in ultrasonic imaging, and on the basis, the targeted ultrasonic contrast agent can be quickly combined with the plaque region to generate strong signal enhancement in ultrasonic imaging. The ultrasonic molecular probe releases siRNA for atherosclerotic plaque treatment, and atherosclerotic plaque diagnosis and treatment integration is achieved. The invention further discloses a preparation method of the ultrasonic molecular probe and application of the ultrasonic molecular probe in preparation of atherosclerotic plaque diagnostic agents, drugs and drug delivery agents.

The disclosure relates to methods, compositions, and combinations for detoxification in a patient comprising performing therapeutic plasma exchange (TPE) on the patient. The disclosure also relates to methods, compositions, and combinations for removing toxins in a patient as a result of chronic exposure to the toxins, comprising performing one or more TPE sessions on the patient and administering an oral composition to the patient. The methods, compositions, and combinations of the disclosure may also be used to replenish biomarkers indicative of a healthy state of the body in order to improve immune system function or patient longevity, and / or reduce oxidative stress or inflammation. The methods, compositions, and combinations of the disclosure may also be used to reduce the level of atherosclerosis, improve cognitive function, prevent early cancer development, promote immune health, and / or treat health conditions or diseases such as autoimmune diseases, cancers, Alzheimer's disease, Parkinson's disease, chronic fatigue syndromes, or fibromyalgia. Additionally, the methods, compositions, and combinations of the disclosure may comprise an intravenous supplementation, wherein each TPE session is followed by administration to the patient of an IV composition. The disclosure further relates to oral compositions and IV compositions for use in the methods, compositions, and combinations of the disclosure.

The invention belongs to the technical field of biological medicines, and particularly relates to application of a macrophage Angulin-1 gene and / or an Angulin-1 protein in preparation of medicines and diagnostic products for preventing and / or treating atherosclerosis and related diseases. Research finds that plaque and necrotic core areas of an atherosclerosis animal model are remarkably increased due to macrophage Angulin-1 gene knockout, and disease development is promoted; and the recovery of the expression level of Angulin-1 significantly inhibits the development of lesion. Cell experiments show that Angulin-1 reduces intake of oxidized low-density lipoprotein by down-regulating expression of macrophage LOX-1, so that formation of foam cells is inhibited. Therefore, the macrophage Angulin-1 can be used as an atherosclerosis drug target, a gene therapy target gene and an auxiliary diagnosis marker, and a new theoretical basis and an intervention strategy are provided for prevention and treatment of the disease.

The present application provides a variety of salts of 25HC3S, including crystalline salts of 25HC3S. Provided herein are pharmaceutical formulations of the salts of the invention, and methods of treating or preventing diseases therewith, the diseases such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), alcoholic hepatitis, acute kidney injury (AKI), psoriasis, atherosclerosis, hypercholesterolemia, hypertriglyceridemia, alcoholic fatty liver disease (AFLD), alcoholic steatohepatitis (ASH), leptin resistance, leptin deficiency, diabetic conditions, autoimmune conditions, inflammatory conditions, and the like. Nervous system disorders, EB virus related growth, and disorders associated with fat accumulation and inflammation. Methods of making the salts of the present application are also provided.

The invention discloses a method and a system for intelligently analyzing heterogeneity of endothelial cells in atherosclerosis. The method comprises the following steps: acquiring sample data of the endothelial cells in the atherosclerosis of a patient; performing feature extraction on the sample data of the endothelial cells to obtain gene expression features of the endothelial cells; dividing the endothelial cells into different subgroups according to gene expression characteristics of the endothelial cells and gene expression similarity so as to determine marker genes for distinguishing the different subgroups, and defining and representing characteristics of each subgroup by analyzing expression modes of the marker genes; gene expression differences among different endothelial cell subgroups are compared, differential expression genes of the related endothelial cell subgroups, which are significantly up-regulated or down-regulated in the atherosclerosis process, are identified, and the differential expression genes are used as key molecular markers for understanding functional changes and heterogeneity of endothelial cells. According to the method, the heterogeneity of the endothelial cells in the atherosclerosis can be accurately analyzed.

The invention belongs to the field of active peptides, and particularly relates to application of selenium-rich polypeptide in inhibiting NLRP3 inflammasome-related inflammations and regulating cholesterol transport protection lipid metabolism abnormality, the selenium-rich polypeptide is prepared by chelating Adi-Apo fusion protein as shown in SEQ ID NO: 3 and sodium selenite (Na2SeO3); the selenium peptide chelate has the effects of remarkably reducing the concentration of TC / TG in serum, reducing the liver lipid deposition and inflammation level and reducing the atherosclerotic plaque area proportion through high oxidation resistance and high anti-inflammatory activity, and can be used for treating and / or preventing lipid metabolism disorder diseases such as metabolism-related fatty liver diseases and coronary atherosclerosis.

The application presently discloses a method of treating atherosclerosis in a human subject comprising administering an effective amount of an IL-8 inhibitor, an IL-6 inhibitor, and / or an IL-1β inhibitor, wherein the subject has a TET2 and / or DNMT3A mutation thereby treating atherosclerosis. It also discloses a method for treating atherosclerosis in a human subject comprising sequencing at least a part of a genome comprising TET2 and / or DNMT3A of one or more cells in a blood sample of the subject; determining from the sequencing whether the subject has one or more mutations in TET2 and / or DNMT3A, if it is determined that the subject has at least one TET2 and / or DNMT3A mutation, administering an IL-8 inhibitor, an IL-6 inhibitor, and / or an IL-1β inhibitor to a subject to the subject thereby treating atherosclerosis.

The invention provides a nano-drug for targeted diagnosis and treatment of atherosclerotic plaque, the nano-particles are constructed by EGCG, formaldehyde and L-arginine, the antioxidant characteristic of EGCG is retained, and the nano-drug constructed by modifying Mn < 2 + > and DKK1 antibodies on the basis has a good relaxation value and can be used for an atherosclerotic plaque specific MRI imaging enhancer; the Cy5-labeled nano-drug can be used for an atherosclerotic plaque specific in-vivo imaging developer. The nano-drug provided by the invention has good biological safety, can delay plaque development and improve plaque stability, and is a nano-drug for precisely targeting atherosclerotic plaque and treating the atherosclerotic plaque.

The invention provides a fluorescent probe for detecting hydroxyl radicals as well as a preparation method and application thereof, and the preparation method comprises the following steps: (S10) synthesizing a first intermediate compound by taking 2, 3, 3-trimethyl-3H-indoline and methyl iodide as raw materials; (S20) synthesizing a second intermediate compound by taking phosphorus trichloride, cyclohexanone and anhydrous dimethylformamide as raw materials; (S30) mixing and reacting the first intermediate compound and the second intermediate compound to synthesize a compound IR780; and (S40) synthesizing OH-probe on the basis of the IR780. The prepared OH-probe has extremely high sensitivity and excellent selectivity on hydroxyl radicals, can be effectively used for monitoring and mapping the level of the hydroxyl radicals, and can be applied to detection of atherosclerosis, obesity, cancers, neurodegenerative diseases, inflammatory diseases and other free radical related diseases. Wide development prospects and practical application values are realized.

The present invention belongs to the field of medical technology, and discloses a liposome that actively targets atherosclerotic plaques and its application in diagnosis. The carrier material forming the liposome includes a targeting peptide R8 modified with methoxy polyethylene glycol phospholipid (R8-DSPE-PEG), polysulfide propylene-polyethylene glycol (PPS-PEG) and cholesterol (CH), and the sequence of the targeting peptide R8 is Asp-Ser-Ser-Ser-Gln-Cys-His-Arg. The liposome of the present invention can increase the enrichment concentration of fluorescent dyes or drugs in the local lesion, has the advantages of low toxicity and high efficiency, and the obtained targeted liposome has a good effect on the diagnosis of atherosclerosis.

The invention provides a theaflavin composition for treating hypertension as well as a preparation method and application thereof, and relates to the technical field of medicines. The theaflavin composition comprises theaflavin, a celery seed extract, a gastrodia elata extract, a parasitic loranthus extract, a centella asiatica extract, a lotus leaf extract and a licorice extract. Wherein the theaflavin can regulate blood fat, inhibit atherosclerosis and improve the vascular endothelial function; the celery seed extract inhibits the activity of angiotensin converting enzyme, and cooperates with theaflavin to regulate blood pressure; the gastrodia elata extract can calm liver wind and improve cerebral circulation; the loranthus parasiticus extract has the effects of tonifying liver and kidney and regulating water sodium metabolism; the centella asiatica extract can resist inflammation and repair vascular endothelium; the lotus leaf extract can clear heat, promote diuresis, calm the liver and suppress yang; and the licorice extract harmonizes the medicines and resists oxidation. According to the invention, theaflavin is taken as a core, multi-dimensional effects of reducing blood pressure, protecting blood vessels and resisting inflammation and oxidation are realized, and a natural and comprehensive health management scheme is provided for hypertensive patients.

The invention belongs to the technical field of biological medicine and electronic information technology, and discloses an atherosclerosis model based on nano-molecule magnetic resonance imaging and a machine learning algorithm, a nano-targeting probe and application of the atherosclerosis model based on the nano-molecule magnetic resonance imaging and the machine learning algorithm. A high-resolution MRI image capable of specifically displaying foam macrophage distribution in the plaque is obtained; then, image omics features are extracted from the images, a machine learning model which is constructed based on the features and verified by pathological labels is adopted for analysis, and finally an objective and quantitative plaque vulnerability score is output. According to the model disclosed by the invention, an objective and quantitative risk score can be output by fusing nano-targeted molecular imaging and machine learning, and accurate and reliable quantification of plaque vulnerability is realized. According to the invention, through systematic integration of targeted molecular imaging and machine learning, significant technical progress is brought.

The invention relates to an application of a histone H3K18 lactic acid modification related target in preparation of a medicine for preventing or treating atherosclerosis. The invention belongs to the field of biological medicine, and discloses histone acetyltransferase P300 and application of histone H3K18 lactylation (H3K18la) modification mediated by the histone acetyltransferase P300 as a new target spot for treating atherosclerosis (AS). Researches find that in the AS process, lactic acid accumulation in vascular smooth muscle cells (VSMCs) up-regulates H3K18la through P300 catalysis, and then the pathological phenotype of the VSMCs is induced, and plaque development is promoted. H3K18la can be reduced and the phenotype can be improved by inhibiting LDHA and MCT1 in vitro or knocking out a P300 gene; the P300 for in-vivo targeted inhibition of the VSMCs can significantly reduce the artery plaque. Therefore, the P300 and H3K18la inhibitors can be used for preparing the anti-atherosclerosis medicine.

The invention relates to the technical field of biological medicines, and provides a self-assembled polypeptide-rhein conjugate, a preparation as well as a preparation method and application of the self-assembled polypeptide-rhein conjugate. The sequence of the MMP-9 responsive self-assembled polypeptide-rhein conjugate is Rhein-GFFPLGLAGACE, and the MMP-9 responsive self-assembled polypeptide-rhein conjugate can respond to abnormally activated MMP-9 in atherosclerotic plaque and is self-assembled into a stable nanofiber structure in situ at a diseased region; the anti-inflammatory and anti-oxidation functions of rhein in the conjugate are remarkable, but the water solubility and oral bioavailability are low, the anti-inflammatory and anti-oxidation functions are remarkably improved after being coupled with the polypeptide, targeted delivery is achieved, and the residence time is prolonged; the introduction of the tripeptide ACE simulating the function of glutathione further enhances the oxidative stress resistance of the conjugate. Furthermore, the conjugate shows excellent anti-inflammatory and anti-oxidation effects, can clear ROS, inhibit inflammation pathways, regulate macrophage phenotypes and inhibit apoptosis, and provides a new strategy for treatment of atherosclerosis.

The invention discloses an atherosclerotic plaque risk assessment method and system based on artificial intelligence, relates to the technical field of medical image analysis, and provides the following scheme: synchronously acquiring medical image sequence and physiological signal time sequence data, generating a synchronization data set through time-space registration, and performing time-space registration on the synchronization data set; and inputting the synchronized data set into a pre-trained LSTM neural network, and outputting a dynamic artifact offset field which represents a displacement vector of a medical image pixel point along with a physiological signal phase. Gradient amplitude analysis is performed on the medical image sequence frame by frame to generate the gradient characteristic evolution graph, high, medium and low response areas are divided according to the dynamic gradient threshold interval, and the displacement correction vectors are configured for the areas, so that the problem of gradient response heterogeneity compensation deficiency in a conventional correction strategy is solved, adaptive deformation correction of an anatomical structure is realized, and the correction accuracy is improved. And low-gradient region structure dispersion and vascular wall edge sharpness attenuation caused by global compensation are inhibited.

Implemented is a catheter for removing material in a body lumen. The catheter includes a catheter tube, a flexible drive shaft, an infusion lumen, an extraction lumen, and a head configured to remove the material in the body lumen. The head includes a housing connected to the catheter tube. The housing includes an infusion aperture fluidly coupled to the infusion lumen, an extraction aperture fluidly coupled to the extraction lumen, and a cutting chamber having a cutout therein. The head further includes a balloon and a probe connected to and driven by the flexible drive shaft. The probe is disposed within the cutting chamber, and the probe is configured to remove the material from the body lumen, at the cutout, and pulverize the material within the cutting chamber.

The application discloses a method for constructing a mouse model of atherosclerosis induced without high-fat diet, and relates to the technical field of disease model construction.The mouse model construction method provided by the application obtains a mouse model that spontaneously exhibits atherosclerosis symptoms without high-fat diet induction.The mouse model of atherosclerosis induced without high-fat diet can be used for researching the pathogenesis of atherosclerosis and screening and evaluating drugs for atherosclerosis.

The invention provides a calcification section coronary artery risk prediction method and device based on chest CT (Computed Tomography) plain scanning. The method comprises the following steps: firstly, acquiring and screening chest CT (Computed Tomography) plain-scan image data; secondly, performing calcification section coronary artery labeling on the image data; thirdly, performing CCTA image interpretation and grouping on the marked areas; and finally, collecting a CT image and a classification label model corresponding to the CT image, using a ResTransNet network to extract features from the calcification section coronary artery label, training the ResTransNet model, and predicting a risk state. According to the method, the deep learning method is applied to the coronary artery of the calcification section of chest CT flat scanning, the plaque type and the blood vessel stenosis degree are accurately predicted, and effective information is provided for subclinical coronary atherosclerosis risk screening and prevention; constructing plaque types and coronary artery stenosis degrees gt; and the prediction device has great clinical significance when being used for screening the risk of subclinical coronary atherosclerosis.

The invention relates to application of a chest stuffiness relieving composition in preparation of a medicine for preventing and / or treating atherosclerosis. The effective components in the chest stuffiness relieving composition can adjust the pathological processes through various ways, so that the effect of preventing and treating atherosclerosis is achieved. Through repositioning of the chest widening composition, the clinical application range of the chest widening composition is expanded, and a more comprehensive and effective atherosclerosis treatment method is provided.